Mereo BioPharma Group plc (MREO) États Financiers et Données Historiques

Mereo BioPharma Group plc (MREO) — Prix $0.27 HealthcareBiotechnology — NASDAQ

Derniers résultats publiés:

États financiers détaillés de Mereo BioPharma Group plc (MREO): compte de résultat, bilan et tableau de flux de trésorerie. Suivez l'évolution des marges, de la dette, de la liquidité et de la rentabilité d'une année sur l'autre avec jusqu'à 20 ans d'historique.

Résumé de l'Analyse

Marges des 12 derniers mois: marge brute 0.0%, marge opérationnelle 0.0%, marge nette 0.0%.

Au prix actuel de $0.27, MREO affiche des résultats négatifs (PER non significatif) et un ROE de -74.76%. La capitalisation boursière s'établit à $42M.

Compte de Résultat (10 ans)

Année2016201720182019202020212022202320242025
Revenus0-$3.3M000$49.2M0$10.0M0$500000
Coût des Ventes$24.6M$34.6M$22.7M$2.0M$2.1M$24.2M-$1.1M$2.6M0$133000
Marge Brute-$24.6M-$37.9M-$22.7M-$2.0M-$2.1M$25.0M$1.1M$7.4M0$367000
R&D$24.6M$34.6M$22.7M$30.1M$21.0M$31.8M$29.5M$17.4M0$17.8M
Frais Généraux$11.6M$10.7M$12.5M$18.3M$25.2M$21.5M$26.1M$18.4M0$23.0M
Charges Opérationnelles$11.6M$10.7M$12.5M$48.4M$46.1M$53.3M$55.6M$35.8M0$38.6M
Résultat Opérationnel-$36.2M-$45.3M-$35.2M-$50.4M-$48.2M-$28.3M-$54.4M-$28.4M0-$38.3M
EBITDA-$38.4M-$44.4M-$34.9M-$44.6M-$203.4M$25.5M-$37.9M-$26.1M0-$40.5M
Charges d'Intérêt$179765$1.1M$2.4M$3.5M$6.4M$5.2M$4.2M$2.9M0$255000
Résultat Avant Impôts-$33.7M-$47.0M-$37.3M-$52.5M-$213.4M$19.2M-$42.9M-$30.0M0-$41.9M
Impôts-$5.3M-$8.2M-$5.3M-$8.0M-$3.6M$2.0M-$718000-$53200000
Résultat Net-$28.4M-$38.8M-$32.0M-$44.5M-$209.8M$17.2M-$42.2M-$29.5M0-$41.9M
BPA$-19553.91$-19003.80$-14352.87$-12902.58$-16503.30$749.65$-1.80$-1100.22$0.00$-0.26
BPA Dilué$-19553.91$-19003.80$-14352.87$-12902.58$-16503.30$749.65$-1.80$-1100.22$0.00$-0.26
Actions en Circulation (Diluées)$9.0M$13.8M$14.2M$17.9M$67.8M$116.7M$22.8M$131.9M0$159.4M

Bilan (10 ans)

Année2016201720182019202020212022202320242025
Trésorerie$53.6M$50.0M$25.0M$20.9M$31.3M$126.7M$68.2M$57.4M$69.8M$41.0M
Placements à Court Terme0$2.5M$2.5M$720634$748034$7694700000
Créances$995784$5093500000$3.2M$3.7M$3.2M$2.0M
Stocks-$53.9M-$2.5M-$2933280000000
Actifs Courants$60.8M$63.2M$34.5M$40.3M$40.7M$134.3M$75.2M$63.8M$74.8M$45.0M
Immobilisations Corporelles$173869$153361$148935$15.3M$2.2M$3.4M$2.2M$1.6M$984000$381000
Goodwill0000000000
Actifs Incorporels$25.8M$33.0M$32.6M$58.9M$43.3M$33.2M$29.0M$1.1M$643000$516000
Actifs Totaux$86.8M$96.3M$67.3M$114.5M$86.1M$171.0M$77.4M$66.5M$76.4M$45.9M
Dettes Fournisseurs$1.2M$2.6M$5.6M$8.1M$4.3M$3.1M$3.5M$2.3M$2.4M$1.3M
Dette à Court Terme0$1.9M$6.8M$20.1M00$13.3M0$5.5M0
Passifs Courants$3.2M$9.6M$16.2M$39.6M$11.7M$17.0M$24.4M$9.5M$13.8M$4.3M
Dette à Long Terme$3.1M$18.8M$14.6M$7.1M$22.1M$19.5M0$4.4M00
Passifs Totaux$7.5M$33.9M$34.5M$61.2M$106.6M$51.9M$26.0M$16.0M$15.4M$5.0M
Réserves-$33.6M-$79.3M-$111.2M-$193.5M-$423.5M-$401.6M-$404.6M-$419.6M-$462.9M-$501.0M
Capitaux Propres$79.3M$62.5M$32.8M$53.3M-$20.5M$119.0M$51.4M$50.5M$61.0M$40.9M
Dette Totale$3.1M$20.8M$21.5M$42.9M$24.5M$22.7M$15.4M$6.0M$6.4M$202000
Dette Nette-$50.5M-$31.8M-$6.1M$21.3M-$7.6M-$104.9M-$52.8M-$51.5M-$63.4M-$40.8M
Fonds de Roulement$57.6M$53.6M$18.3M$737856$28.9M$117.4M$50.8M$54.3M$60.9M$40.7M

Tableau de Flux (10 ans)

Année2016201720182019202020212022202320242025
Résultat Net-$33.7M-$47.0M-$37.3M-$53.9M-$226.8M$19.2M-$42.2M-$29.5M-$43.3M-$41.9M
Amortissements$32940$36076$37796$2.1M$2.2M$866466$889000$1.1M$1.1M$622000
Stock-based Compensation$6.5M$3.7M$2.2M$2.1M$2.1M$4.5M$4.8M$4.9M$7.4M$7.6M
Variation du BFR-$2.0M$3.0M$2.4M-$10.1M-$4.6M-$2.5M-$2.4M-$1.6M-$369000-$3.2M
Cash Flow Opérationnel-$27.4M-$32.1M-$23.1M-$60.2M-$38.6M-$7.1M-$48.8M-$21.1M-$32.8M-$31.0M
CapEx-$3467-$2.3M-$35536-$27534-$21805-$722055-$13000-$419000-$699000-$20000
Acquisitions000$13.2M-$48244000000
Rachat d'Actions00-$306838-$1.3M000000
Dividendes Payés0000000000
Free Cash Flow-$27.4M-$34.4M-$23.2M-$60.3M-$38.6M-$7.8M-$48.8M-$21.6M-$33.5M-$31.0M

Croissance et Marges (10 ans)

Année2016201720182019202020212022202320242025
Croissance Revenus (annuelle)+100.0%-100.0%-100.0%
Croissance Résultat Net (annuelle)-36.7%+17.4%-38.8%-372.0%+108.2%-345.8%+30.2%+100.0%
Croissance BPA (annuelle)+2.8%+24.5%+10.1%-27.9%+104.5%-100.2%-61023.3%+100.0%
Variation Actions (annuelle)+54.1%+3.1%+25.7%+279.0%+72.2%-80.5%+478.5%-100.0%
Croissance FCF (annuelle)-25.7%+32.7%-160.0%+35.9%+79.8%-526.7%+55.9%-55.6%+7.6%
Marge Brute1153.4%50.9%74.3%73.4%
Marge Opérationnelle1379.0%-57.4%-284.2%-7651.4%
Marge EBITDA1352.7%51.8%-260.6%-8094.8%
Marge Nette1181.0%34.9%-294.7%-8375.6%
Marge FCF1048.4%-15.8%-215.5%-6198.2%
Taux d'Imposition Effectif15.8%17.4%14.1%15.3%1.7%10.6%1.7%1.8%-0.0%

Données par Action (10 ans)

Année2016201720182019202020212022202320242025
FCF par Action$-3.06$-2.50$-1.63$-3.37$-0.57$-0.07$-2.14$-0.16$-0.19
Dividende par Action$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Actions en Circulation (Basiques)$9.0M$13.8M$14.2M$17.9M$67.8M$116.7M$22.8M$131.9M0$159.4M

Quoi regarder en Biotech

La plupart des petites biotechs perdent de l'argent. Les analyser avec le P/E n'a aucun sens — regardez cash et pipeline.

Rentabilité

Rentabilité des capitaux propres-74.76%
Rentabilité du capital investi-111.41%
Rentabilité des actifs-80.88%
Marge brute0.00%
Marge opérationnelle0.00%
Marge nette0.00%

Santé financière

Dette / Capitaux propres0.04
Ratio de liquidité5.88
Piotroski F-Score4
Altman Z-Score-8.98

Ratios Clés (10 ans)

Année2016201720182019202020212022202320242025
PER-0.00-0.00-0.00-0.00-0.000.00-0.42-0.000.00-1.60
P/B0.731.442.821.10-11.851.570.336.030.001.62
P/V0.00-27.310.000.000.003.800.0030.470.00132.86
Marge Brute0.0%1153.4%0.0%0.0%0.0%50.9%0.0%74.3%0.0%73.4%
Marge Opérationnelle0.0%1379.0%0.0%0.0%0.0%-57.4%0.0%-284.2%0.0%-7651.4%
Marge Nette0.0%1181.0%0.0%0.0%0.0%34.9%0.0%-294.7%0.0%-8375.6%

Entreprises liées: ACIU · ALDX · CADL · CAPR · CTNM · IMMP · KYTX

Explorer le secteur: Healthcare · Biotechnology

Plus de sections de MREO: Vue d'ensemble · Valorisation · Statistiques · Estimations · Technique · Actionnariat · Actualités · Événements

Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions